D. Boral Capital Reaffirms “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $18.00 price target on the stock. D. Boral Capital’s target price suggests a potential upside of 216.90% from the stock’s previous close.

A number of other equities analysts also recently weighed in on COYA. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday. Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Lake Street Capital started coverage on shares of Coya Therapeutics in a research note on Wednesday, July 9th. They set a “buy” rating and a $16.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, June 9th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Coya Therapeutics Stock Performance

Shares of COYA opened at $5.68 on Wednesday. The company has a market capitalization of $95.03 million, a price-to-earnings ratio of -4.58 and a beta of 0.26. The company’s 50 day simple moving average is $5.96 and its 200 day simple moving average is $6.08. Coya Therapeutics has a 1 year low of $4.65 and a 1 year high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.14). The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.78 million. Equities analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Trading of Coya Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Northern Trust Corp increased its holdings in Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after purchasing an additional 3,099 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Coya Therapeutics by 1,005.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after purchasing an additional 4,777 shares in the last quarter. Geode Capital Management LLC increased its holdings in Coya Therapeutics by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock valued at $863,000 after purchasing an additional 8,267 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Coya Therapeutics in the 1st quarter valued at $65,000. Finally, XTX Topco Ltd acquired a new stake in Coya Therapeutics in the 4th quarter valued at $59,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.